“Committed to Excellence in Life Sciences Executive Search”
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in advancing the clinical pipeline at Aeglea as they work to unlock the potential of engineered human enzymes to develop treatment options for patients with rare genetic diseases. The Chase Group is proud to connect this patient focused company with high caliber talent and wish Aeglea the best of success.
Alexza Pharmaceuticals stands at the crossroads of innovation and advanced technology with a platform that has the potential to address unmet medical needs in neuroscience….
The Chase Group (TCG) is pleased to announce the successful recruitment of David Geller, MD as the Vice President, Pulmonary and Rare Diseases Clinical Development…
Ionis Pharmaceuticals retained The Chase Group to identify and secure the next member of their drug safety leadership team to support a robust and continually…
The Chase Group, known for its thorough search capabilities and expertise in Life Sciences Executive Search, was retained by Genmab Pharmaceuticals to execute a critical…
Building on a 14+ year relationship with Chase, the Chief Medical Officer of Checkmate Pharmaceuticals retained The Chase Group to identify a critical hire for…
The Chase Group was once again retained by Akcea Therapeutics to complete an extensive executive search on an accelerated timeline for a Senior Vice President,…